Our study is aimed at identifying the potential of survivin as a therapeutic target in the GSC compartment and suggesting a novel therapeutic strategy for directly targeting this multifunctional protein, thereby improving the overall drug response in GBM. Here, BIRC5 is linked to glioblastoma.